并发重症抑郁障碍的卵巢癌患者血IL-6水平与HPA活化的研究

目的比较是否并发抑郁症的卵巢癌患者血IL-6水平和DST的差异，并探讨抑郁程度与IL-6和DST阳性率的相关性。方法平均分为四组：对照组、患有抑郁症的患者、未患抑郁症的卵巢癌患者、患有抑郁症的卵巢癌患者。选择符合CCMD-2-R中抑郁发作的诊断标准的患者。抑郁症的严重程度由汉密尔顿抑郁量表测定。进行血IL-6测定及地塞米松抑制试验。结果并发抑郁症的卵巢癌患者血浆IL-6水平均比其他组明显高。患者对小剂量地塞米松抑制试验呈现超敏感现象，为该类患者存在持久亢进的垂体-肾上腺轴功能的假说提供了证据。结论通过了解并发重症抑郁障碍的卵巢癌患者血浆地塞米松和IL-6水平的变化，对探讨卵巢癌并发重症抑郁障碍的神经内分泌和神经免疫学发病机制将有深远的意义。

Interleukin-6 Levels and HPA Axis Activation in Ovarian Carcinoma Patients with Major Depressive Disorder

Objective To compare the difference between whether ovarian carcinoma patients with or without major depression exhibit plasma IL-6 abnormalities and dexamethasone suppression test results. Methods Four groups, each consisting of 30 women （ 1-healthy women, 2-patients with depression, 3-ovarian carcinoma patients without depression, 4-ovarian carcinoma patients with major depression）, were compared to each other. Severity of depression was measured with the Hamilton Depression Rating Scale. Plasma levels of interleukin-6 were measured. A dexamethasone suppression test was applied. Results Ovarian carcinoma patients with depression had markedly higher plasma levels of interleukin-6 than the other group. All ovarian carcinoma patients with depression had abnormal dexamethasone suppression test results. These findings suggest a hypothalamo-pituitary-adrenal axis activation and plasma levels of interleukin-6 and plasma interleukin-6 elevation and plasma levels if interleukin-6 and plasma levels of post cortisol concentrations. Conclusion Evidence for a casual link or association of major depression with immune and endocrinological activation needs to be investigated further.